StockData
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. (CMMB) stock

CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 5/30
$1.53+0.13 (+9.29%)

Close on Nov 13, 2026Market cap $11.00MP/E 1.1Yield –

Chemomab Therapeutics cash

Cash and short-term investments held at the end of each period.

Chemomab Therapeutics's cash was $6.70M at Jun 30, 2026. For fiscal 2025 it was $10.40M, down 27.3% from the year before. Over ten years it grew 16.8% a year on average. The highest annual figure on record is $15.24M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.40M-27.3%
FY2024Dec 31, 2024$14.30M+52.6%
FY2023Dec 31, 2023$9.37M-31.1%
FY2022Dec 31, 2022$13.60M-10.8%
FY2021Dec 31, 2021$15.24M+30.0%
FY2020Dec 31, 2020$11.73M-4.5%
FY2019Dec 31, 2019$12.28M+60.8%
FY2018Dec 31, 2018$7.64M+425.2%
FY2017Dec 31, 2017$1.45M-68.1%
FY2016Dec 31, 2016$4.56M+107.2%
FY2015Dec 31, 2015$2.20M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.70M+31.1%
Q4 FY2025Dec 31, 2025$10.40M+11.0%
Q2 FY2025Jun 30, 2025$9.50M-9.1%
Q4 FY2024Dec 31, 2024$14.30M-31.1%
Q2 FY2024Jun 30, 2024$5.11M-62.4%
Q4 FY2023Dec 31, 2023$9.37M-12.8%
Q2 FY2023Jun 30, 2023$10.46M+5.0%
Q1 FY2023Mar 31, 2023$20.77M+49.3%
Q4 FY2022Dec 31, 2022$13.60M-10.8%
Q3 FY2022Sep 30, 2022$10.74M-71.6%
Q2 FY2022Jun 30, 2022$9.96M-78.1%
Q1 FY2022Mar 31, 2022$13.91M-76.1%
Q4 FY2021Dec 31, 2021$15.24M+30.0%
Q3 FY2021Sep 30, 2021$37.80M+197.0%
Q2 FY2021Jun 30, 2021$45.45M+247.4%
Q1 FY2021Mar 31, 2021$58.23M+437.4%
Q4 FY2020Dec 31, 2020$11.73M-4.5%
Q3 FY2020Sep 30, 2020$12.73M-45.2%
Q2 FY2020Jun 30, 2020$13.08M-51.6%
Q1 FY2020Mar 31, 2020$10.84M-66.3%
Q4 FY2019Dec 31, 2019$12.28M+60.8%
Q3 FY2019Sep 30, 2019$23.24M+1498.4%
Q2 FY2019Jun 30, 2019$27.00M+491.7%
Q1 FY2019Mar 31, 2019$32.13M+1358.6%
Q4 FY2018Dec 31, 2018$7.64M–
Q4 FY2017Dec 31, 2017$1.45M–
Q4 FY2016Dec 31, 2016$4.56M–
Q4 FY2015Dec 31, 2015$2.20M–

More Chemomab Therapeutics figures

See a number that looks wrong?